Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Add-on alpelisib not enough to improve response in HR+ early breast cancer

11 Jun 2019

Adding alpelisib to 24-week neoadjuvant letrozole treatment fails to improve response in patients with HR-positive early breast cancer, according to the results of the phase II NEO-ORB trial.

NEO-ORB randomized 257 postmenopausal women to receive 2.5 mg/day letrozole with either 300 mg/day alpelisib (n=131) or placebo (n=126) for 24 weeks. All women had HR-positive, HER2-negative and T1c–T3 breast cancer. They were grouped according to PIK3CA mutational status.

Patients with PIK3CA mutations in the alpelisib vs placebo arm were older (median, 65.5 vs 61.0 years), more likely to have lymph node involvement (N1 or higher; 35 percent vs 27 percent) and T3-stage tumours (12 percent vs 0 percent).  

The trial did not meet its primary objective of improved objective response (ORR) and pathologic complete response (pCR) rates with alpelisib. ORRs vs placebo were 43 percent vs 45 percent in the PIK3CA mutant cohort and 63 percent vs 61 percent in the PIK3CA wild-type cohort.

PCR rates were low in all groups. Reductions in Ki-67 were similar across treatment arms and cohorts.

In PIK3CA-mutant tumours, the addition of alpelisib yielded a greater decrease in phosphorylated AKT compared with placebo.

The present data suggest that alpelisib does not provide clinical benefit in the neoadjuvant setting, but considering the available clinical and experimental data in other indications, adding alpelisib to letrozole may still be an effective treatment strategy for HR+ advanced/metastatic breast cancer that harbours somatic alterations in the PI3K pathway, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.